JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells

Abstract.We recently identified two thiazolidin compounds, 5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone (MMPT) and 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin (DBPT), that inhibit the growth of human non-small-cell lung and colon cancer cells independent of P-glycoprotein and p53 status. Here we further investigated the mechanism by which these thiazolidin compounds mediate their anticancer effects. Treatment of cancer cells with MMPT and DBPT led to a time-dependent accumulation of cells arrested in the G2/M phase with modulation of the expression of proteins such as cyclin B1, cdc25C, and phosphorylated histone H3. Moreover, treatment with MMPT and DBPT increased M-phase arrest with abnormal spindle formation. DBPT-mediated G2/M phase arrest and phosphorylation of cdc25C and histone H3 were abrogated when JNK activation was blocked either with SP600125, a specific JNK inhibitor, or a dominant-negative JNK1 gene. Moreover, DBPT-mediated microtubule disruption was also blocked by SP600125 treatment. Our results demonstrate that thiazolidin compounds can effectively induce G2/M arrest in cancer cells and that this G2/M arrest requires JNK activation.

[1]  J. Correia,et al.  Physiochemical aspects of tubulin-interacting antimitotic drugs. , 2001, Current pharmaceutical design.

[2]  B. Hill,et al.  Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. , 2000, Cancer research.

[3]  S. Lippman,et al.  Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[5]  R. Tishler,et al.  Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. , 1995, Cancer research.

[6]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.

[7]  Jack A Roth,et al.  The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. , 2002, Molecular cancer therapeutics.

[8]  M. Parmar,et al.  First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. , 1998, British Journal of Cancer.

[9]  S. Leach,et al.  Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth Arrest* , 1998, The Journal of Biological Chemistry.

[10]  I. Bosch,et al.  P-glycoprotein multidrug resistance and cancer. , 1996, Biochimica et biophysica acta.

[11]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  M. Morris,et al.  An Essential Phosphorylation-site Domain of Human cdc25C Interacts with Both 14-3-3 and Cyclins* , 2000, The Journal of Biological Chemistry.

[13]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[14]  T. Fojo,et al.  Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. , 1997, Cancer research.

[15]  P. Dent,et al.  Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. , 1999, Biochemical and biophysical research communications.

[16]  R. K Srivastava,et al.  Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Pietenpol,et al.  Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner , 2001, Oncogene.

[18]  S. Haldar,et al.  Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. , 1998, International journal of oncology.

[19]  M. Kavallaris,et al.  Microtubule alterations and resistance to tubulin-binding agents (review). , 2002, International journal of oncology.

[20]  D. Glover,et al.  Drosophila Aurora B Kinase Is Required for Histone H3 Phosphorylation and Condensin Recruitment during Chromosome Condensation and to Organize the Central Spindle during Cytokinesis , 2001, The Journal of cell biology.

[21]  E. Lazarides,et al.  Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.

[22]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[23]  Wei Guo,et al.  Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. , 2005, Cancer research.

[24]  G. Borisy,et al.  Anaphase onset and dephosphorylation of mitotic phosphoproteins occur concomitantly. , 1989, Journal of cell science.

[25]  B. Fang,et al.  P-Glycoprotein-Independent Apoptosis Induction by a Novel Synthetic Compound, MMPT [5-[(4-Methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone] , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  R. Johnstone,et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[28]  R. Perez-soler,et al.  Phosphorylation of Bcl-2 Is a Marker of M Phase Events and Not a Determinant of Apoptosis* , 1998, The Journal of Biological Chemistry.

[29]  Bruce Goldman,et al.  Multidrug resistance: can new drugs help chemotherapy score against cancer? , 2003, Journal of the National Cancer Institute.

[30]  A. Hyman,et al.  Coupling cell division and cell death to microtubule dynamics. , 1997, Current opinion in cell biology.